S.yasseen, S., Mubarak, A. (2024). Response rate to the first line chemotherapy and progression free survival in Iraqi women with advanced epithelial ovarian cancer. , 23(1), 49-58. doi: 10.52573/ipmj.2024.139698
Salma S.yasseen; Ahmed Mubarak. "Response rate to the first line chemotherapy and progression free survival in Iraqi women with advanced epithelial ovarian cancer". , 23, 1, 2024, 49-58. doi: 10.52573/ipmj.2024.139698
S.yasseen, S., Mubarak, A. (2024). 'Response rate to the first line chemotherapy and progression free survival in Iraqi women with advanced epithelial ovarian cancer', , 23(1), pp. 49-58. doi: 10.52573/ipmj.2024.139698
S.yasseen, S., Mubarak, A. Response rate to the first line chemotherapy and progression free survival in Iraqi women with advanced epithelial ovarian cancer. , 2024; 23(1): 49-58. doi: 10.52573/ipmj.2024.139698

Response rate to the first line chemotherapy and progression free survival in Iraqi women with advanced epithelial ovarian cancer

Iraqi Postgraduate Medical Journal
Article 9, Volume 23, Issue 1, January 2024, Pages 49-58    PDF (309.44 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2024.139698
Authors
Salma S.yasseen* 1; Ahmed Mubarak2
1Department of Medical Oncology, College of Medicine, National Teaching oncology hospital, Iraq
2Oncology Teaching Hospital, Medical City Complex
Abstract
Background: Ovarian cancer is the most lethal malignancy of female genital tract. Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms, response rate to platinum, taxan and bevacizumab is excellent in advance stages of disease, despite that recurrence can occur.
Aims: To estimated response rate to first line chemotherapy (platinum and taxane with bevacizumab) and progression free survival (PFS) in patients with advanced epithelial ovarian cancer (OC).
Patients and Methods: A total of 50 patients with OC were enrolled in this cross-sectional study whom received chemotherapy protocols (carboplatin ,paclitaxel and antiangiogenesis { bevacizumab} /Carboplatin) cycle and each cycle repeated every 3 weeks. A response evaluation criterion in solid tumors guidelines was used. Also comparison between primary debulking surgery (PDS) and interval debulking surgery (IDS) in progression free survival (PFS) was measured.
Results: The median baseline level of CA125 was 695 U/ml (range= 9.2-5000 U/ml) compared with 54.6 (range= 5.0-27 U/ml) after treatment (p value < 0.001). The mean ovarian mass before treatment was 6.9±2.62 cm which reduced to 2.5±2.61 cm after treatment (p= 0.001). Similarly, the frequency of lymphadenopathy and ascites decreased from 72% and 68%, respectively before treatment to 22% and 18%, respectively after treatment (p<0.05). One woman (2%) showed disease progression, 3 patients (6%) were stable, 42 patients (84%) had partial response and 4 patients (8%) had complete remission. Mean PFS time for IDS was 19.5±2.82 months, 95%CI= 13.97-25.03 compared with 8.5±2.82 months in PDS, 95%CI= 4.54-12.46 (p=0.008).
Conclusions: Platinum and taxan based with bevacizumab showed effective treatment regime for management of advanced OC and serum level of CA125 could be effectively used in monitoring the disease progression and response. Interval debulking surgery was more effective compared to primary debulking surgery and PFS was better in patient who is done IDS than in patient in PDS.
Keywords
Response,,; ,،,؛progression free survival,,; ,،,؛advanced epithelial ovarian cancer
References
  1. Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019;35:151-56.
  2. Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, Sasieni P,Menon U, et al. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG. 2016;123:1012-20.
  3. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. on behalf of the International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer collaborators. J Natl Cancer Inst 2003;95:105-12.
57
  • Burger R, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010;28.
  1. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, H. Zacur, G W. Comstock, “Prospective study of serum CA-125 levels as markers of ovarian cancer,” Journal of the American Medical Association, 1993;269: 1123–26.
  2. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011;365:2473–83.
  3. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484–96.
  4. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine, E, Kristensen G, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial International Collaborative Ovarian Neoplasm , Adjuvant Chemotherapy in Women With Ovarian Cancer. Lancet Oncol. 2015;16: 928–36.
  5. Matsuhashi T, Takeshita T, Yamamoto A, Kawase R, Yamada T, Kurose K, et al. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer. J Nippon Med Sch. 2017;84:170-76.
  6. Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2012;125: 362-66.
  7. Yang Zj, Zhao Bb, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J Ovarian Res 2016;9:57.
  8. McNulty M, Das A, Cohen PA, Dean A. Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score. Int J Gynecol Cancer. 2019:ijgc-2019-000222.
  9. Wilson MK, Chawla T, Wang L, et al. Inter and intra-observer variability with the assessment of RECIST in ovarian cancer. JCO 2018;36:5555.
  10. Mazzeo F, Berlière M, Kerger J, Squifflet J, Duck L, D'Hondt V, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol. 2003;90:163-69.
  11. Batra S, Nayak H, Dave KS. Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer. J Obstet Gynaecol India. 2012;62:541-45.
  12. Komiyama S, Kato K, Inokuchi Y, Takano H, Matsumoto T, Hongo A, et al. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: A prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol. 2019;24: 103–14.
  13. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–53.
  14. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (chorus): an open-label, randomised, controlled, non-inferiority trial. The Lancet 2015;386:249–57.
  15. Petrillo M, Ferrandina G, Fagotti A, Vizzielli G, Margariti P, Pedone A, et al. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 2013: 3955-60.
 

Statistics
Article View: 309
PDF Download: 143


Journal Management System. Powered by iJournalPro.com